Su Pengli, Zhi Kai, Xu Huanhuan, Xiao Jing, Liu Jun, Wang Zhong, Liu Qiong, Yu Yanan, Dang Haixia
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2024 Apr 24;15:1245825. doi: 10.3389/fphar.2024.1245825. eCollection 2024.
Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment. A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it. Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were "comparative safety/tolerability" (58 times), "comparative effectiveness/efficacy" (56 times), "comparative patient-perceived health/patient reported outcomes" (37 times), "disease severity" (34 times), and "unmet needs" (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were "cost of intervention" (17 times), "comparative other medical costs" (16 times), and "comparative non-medical costs" (18 times). Out of the 10 criteria (18 times) for assessing innovative value, "a novel pharmacological mechanism" was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, "system capacity and appropriate use of intervention" was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, "political/historical/cultural context" was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. "Swing weighting" and "a direct rating scale" were the most frequently used techniques in included articles. This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.
多标准决策分析(MCDA)在支持药物风险效益评估、定价与报销以及临床干预优化方面受到了越来越多的关注。本研究的目的是系统收集和分类用于药物价值评估的MCDA评估标准以及加权和评分技术。我们在七个数据库中对文献进行了系统综述,以识别利用MCDA框架评估药物价值的文章。提取纳入研究中提到的评估标准,并将其分配到临床、经济、创新、社会和人文价值五个维度。对识别出的药物价值评估标准以及所采用的加权和评分技术进行了描述性统计分析。文章中提及某一标准或技术的次数越多,我们认为其越重要。在纳入的82篇文章中,共识别出111条评估药物价值的独特标准。在用于衡量临床价值的56条独特标准(共提及448次)中,最常被提及的是“比较安全性/耐受性”(58次)、“比较有效性/疗效”(56次)、“比较患者感知健康/患者报告结局”(37次)、“疾病严重程度”(34次)以及“未满足需求”(25次)。在衡量经济价值方面,在20条独特标准(共提及124次)中,最常使用的标准是“干预成本”(17次)、“比较其他医疗成本”(16次)以及“比较非医疗成本”(18次)。在评估创新价值的10条标准(共提及18次)中,“新的药理机制”是最常被提及的标准(5次)。在用于衡量社会价值的22条标准(共提及73次)中,“系统能力和干预的合理使用”是最常被引用的标准(14次)。在用于衡量人文价值的3条标准(共提及15次)中,“政治/历史/文化背景”是最常被提及的标准(9次)。此外,从各种MCDA框架中发现了11种评分技术和11种加权技术。“摆动加权”和“直接评分量表”是纳入文章中最常使用的技术。本研究全面呈现了当前以药物为导向的MCDA文章中的评估维度、标准以及评分和加权技术。通过突出经常被引用的评估标准以及评分和加权技术,本分析将为在构建与研究目标相符的MCDA框架时合理选择合适的评估标准和技术提供基础。